Search Results - "Wu, Frank S"

The predictability of serum anti-Müllerian level in IVF/ICSI outcomes for patients of advanced reproductive age by Lee, Robert K K, Wu, Frank S Y, Lin, Ming-Huei, Lin, Shyr-Yeu, Hwu, Yuh-Ming

“…The role of serum anti-Müllerian hormone (AMH) as predictor of in-vitro fertilization outcomes has been much debated. The aim of the present study is to…”
Get full text

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma by Flaherty, Keith T, Robert, Caroline, Hersey, Peter, Nathan, Paul, Garbe, Claus, Milhem, Mohammed, Demidov, Lev V, Hassel, Jessica C, Rutkowski, Piotr, Mohr, Peter, Dummer, Reinhard, Trefzer, Uwe, Larkin, James M.G, Utikal, Jochen, Dreno, Brigitte, Nyakas, Marta, Middleton, Mark R, Becker, Jürgen C, Casey, Michelle, Sherman, Laurie J, Wu, Frank S, Ouellet, Daniele, Martin, Anne-Marie, Patel, Kiran, Schadendorf, Dirk

“…Treatment with trametinib, a MEK inhibitor, resulted in significantly improved progression-free and overall survival, as compared with chemotherapy, in…”
Get full text

DREAMM-8: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin with Pomalidomide and Dexamethasone (B-Pd) Vs Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) by Trudel, Suzanne, Davis, Randy, Lewis, Nicole M., Bakshi, Kalpana K., Chopra, Bikramjit, Montes de Oca, Rocio, Ferron-Brady, Geraldine, Eliason, Laurie, Kremer, Brandon E., Gupta, Ira, Wu, Frank S.

“…Introduction: Belantamab mafodotin (belamaf; GSK2857916) is a B-cell maturation antigen (BCMA)-targeting antibody-drug conjugate. In the pivotal Phase II…”
Get full text

The impact of endometrioma and laparoscopic cystectomy on serum anti-Müllerian hormone levels by Hwu, Yuh-Ming, Wu, Frank Shao-Ying, Li, Sheng-Hsiang, Sun, Fang-Ju, Lin, Ming-Huei, Lee, Robert Kuo-Kuang

“…Serum anti-Müllerian hormone (AMH) had been proposed as a marker of ovarian reserve. The aim of this study was to evaluate the impact of endometrioma and…”
Get full text

Tumor-specific circulating cell-free DNA (cfDNA) to predict clinical outcome in BRAF V600 mutation-positive melanoma patients (pts) treated with the MEK inhibitor trametinib (T) or chemotherapy (C) by Schadendorf, Dirk, Flaherty, Keith, Hersey, Peter, Nathan, Paul D., Garbe, Claus, Milhem, Mohammed M., Demidov, Lev V., Hassel, Jessica Cecile, Rutkowski, Piotr, Mohr, Peter, Dummer, Reinhard, Trefzer, Uwe, Larkin, James M. G., Utikal, Jochen, Casey, Michelle, Santiago-Walker, Ademi, Sherman, Laurie Jill, Martin, Anne-Marie, Wu, Frank S., Robert, Caroline

“…Abstract only 9020 Background: Tumor-derived cfDNA in the blood is a potential alternative source to derive tumor mutation (mut) status and could be a useful…”
Get full text

MEK114653: A randomized, multicenter, phase II study to assess efficacy and safety of trametinib (T) compared with docetaxel (D) in KRAS -mutant advanced non–small cell lung cancer (NSCLC) by Blumenschein, George R., Smit, Egbert F., Planchard, David, Kim, Dong-Wan, Cadranel, Jacques, De Pas, Tommaso, Dunphy, Frank, Udud, Katalin, Ahn, Myung-Ju, Hanna, Nasser H., Kim, Joo-Hang, Mazieres, Julien, Kim, Sang-We, Baas, Paul, Rappold, Erica, Redhu, Suman, Bellew, Kevin M., Streit, Michael R. W., Wu, Frank S., Janne, Pasi A.

“…Abstract only 8029 Background: KRAS mutations are detected in 25% of NSCLC, and there are no approved targeted therapies for this subset of NSCLC. D, an…”
Get full text

METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAF V600E/K mutant advanced or metastatic melanoma (MM) by Robert, Caroline, Flaherty, Keith T., Hersey, Peter, Nathan, Paul D., Garbe, Claus, Milhem, Mohammed M., Demidov, Lev V., Hassel, Jessica C., Rutkowski, Piotr, Mohr, Peter, Dummer, Reinhard, Trefzer, Uwe, Larkin, James M. G., Utikal, Jochen, Casey, Michelle, Sherman, Laurie Jill, Crist, Wendy A., Wu, Frank S., Patel, Kiran, Schadendorf, Dirk

“…Abstract only LBA8509 Background: Dacarbazine (D) and paclitaxel (P) have been used to treat MM pts with limited effect. The MM treatment landscape has…”
Get full text

METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS) compared with chemotherapy (C) in patients (pts) with BRAF V600/k mutant advanced or metastatic melanoma (MM) by Robert, Caroline, Flaherty, Keith T., Hersey, Peter, Nathan, Paul D., Garbe, Claus, Milhem, Mohammed M., Demidov, Lev V., Hassel, Jessica C., Rutkowski, Piotr, Mohr, Peter, Dummer, Reinhard, Trefzer, Uwe, Larkin, James M. G., Utikal, Jochen, Casey, Michelle, Sherman, Laurie Jill, Crist, Wendy A., Wu, Frank S., Patel, Kiran, Schadendorf, Dirk

“…Abstract only LBA8509 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Monday, June 4, 2012, and in the Annual…”
Get full text

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma by FLAHERTY, Keith T, ROBERT, Caroline, DUMMER, Reinhard, TREFZER, Uwe, LARKIN, James M. G, UTIKAL, Jochen, DRENO, Brigitte, NYAKAS, Marta, MIDDLETON, Mark R, BECKER, Jürgen C, CASEY, Michelle, SHERMAN, Laurie J, HERSEY, Peter, WU, Frank S, OUELLET, Daniele, MARTIN, Anne-Marie, PATEL, Kiran, SCHADENDORF, Dirk, NATHAN, Paul, GARBE, Claus, MILHEM, Mohammed, DEMIDOV, Lev V, HASSEL, Jessica C, RUTKOWSKI, Piotr, MOHR, Peter

Get full text